FREQUENCY OF DUAL ANTI PLATELET RESISTANCE IN PATIENTS WITH CORONARY ARTERY DISEASE
Article Sidebar
Main Article Content
Abstract
Objectives: To find the frequency of dual antiplatelet resistance in patients with coronary artery disease.
Material and Methods: This study was conducted in the Department of Cardiology, Lady Reading Hospital, Peshawar,
from January 2007 to February 2008. A total of 105 normal individuals not taking any anti platelet drug and 108
patients taking dual anti platelet drugs for coronary artery diseases were included. Blood was taken for measuring
platelet aggregation using whole blood aggregometer and results were recorded on a proforma. Patients who were
on warfarin and heparin were excluded from the study. Chi-square and independent t-test were used to find
significant differences between different groups and variables.
Results: Platelet aggregability in 105 normal subjects, not taking aspirin was 9.28±3.23ohms. So cutoff for dual anti
platelet non responsiveness was taken as 9.28-3.23=6.0 ohms. Patients who were taking dual antiplatelets were
108. Their mean age was 51.94±8.36 years. Male were 64(59.3%) and female were 44(40.7%). Mean aggregability of
all these patients was found to be 3.91±3.50 ohms. Patients having aggregability of >6 ohms (dual antiplatelets
resistance) were 29.6% (n=32), while patients having aggregability of < 6 ohms (dual antiplatelets sensitive) were70.4%
(n=76). Mean aggregability of sensitive patients was 2.06±1.76 ohms, while mean aggregability of resistant patients
was 8.31±2.55 ohms. Mean aggregability of all the male patients was 4.00±3.38 ohms, while mean aggregability of
female patients was 3.79±3.70 ohms. (p=0.769). When age was correlated with aggregability, both have a weak
positive correlation r= .121(p=0.213).
Conclusion: Dual anti platelet resistance as defined by inhibition of platelet aggregation measured with Whole
Blood Aggregometery, is a common problem. Gender and age has no significant affect on platelet aggregability.
Article Details
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.